Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
This review considers master protocols, which involve the study of one or more interventions in multiple diseases or of a single disease with multiple interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C., Kelloff, G., Hylton, N., Berry, D., & Esserman, L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 766
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection
The PREVAIL II Writing Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604330 · Cited by 520
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
The Platform Trial: An Efficient Strategy for Evaluating Multiple Treatments
Berry, S. M., Connor, J. T., & Lewis, R. J. (2015) · JAMA · doi:10.1001/jama.2015.2316 · Cited by 377
Efficiencies of platform clinical trials: A vision of the future
Saville, B. R., & Berry, S. M. (2016) · Clinical Trials · doi:10.1177/1740774515626362 · Cited by 315
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
Berry, S. M., Broglio, K. R., Groshen, S., & Berry, D. A. (2013) · Clinical Trials · doi:10.1177/1740774513497539 · Cited by 229
Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4575 · Cited by 213
The utility of Bayesian predictive probabilities for interim monitoring of clinical trials
Saville, B. R., Connor, J. T., Ayers, G. D., & Alvarez, J. (2014) · Clinical Trials · doi:10.1177/1740774514531352 · Cited by 153
Berry, D. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.02.011 · Cited by 150
Catenacci, D. V. T. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 144
Are outcome-adaptive allocation trials ethical?
Hey, S. P., & Kimmelman, J. (2015) · Clinical Trials · doi:10.1177/1740774514563583 · Cited by 124
Fridlyand, J., Simon, R. M., Walrath, J. C., Roach, N., Buller, R. E., Schenkein, D. P., Flaherty, K. T., Allen, J. D., Sigal, E. V., & Scher, H. I. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4101 · Cited by 89
Innovative Clinical Trials: The LUNG‐MAP Study
Steuer, C., Papadimitrakopoulou, V., Herbst, R. S., Redman, M. W., Hirsch, F., Mack, P. C., Ramalingam, S., & Gandara, D. R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.88 · Cited by 72
Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
Esserman, L. J., & Woodcock, J. (2011) · JAMA · doi:10.1001/jama.2011.1837 · Cited by 69
Self-citationDavis, S. M., Koch, G. G., Davis, C. E., & LaVange, L. M. (2003) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006993 · Cited by 44
Self-citationLet's Not Put All Our Eggs in One Basket
Hunter, D. J., & D’Agostino, R. B. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1508144 · Cited by 17
Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy
Sridhara, R., He, K., Nie, L., Shen, Y.-L., & Tang, S. W. (2015) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2015.1094673 · Cited by 7
Research works printed but not linked: 5
- 10.1038/nm0114-3 · doi:10.1038/nm0114-3
- 10.1093/infdis/jiw061 · doi:10.1093/infdis/jiw061
- 10.1016/j.jaci.2006.06.011 · doi:10.1016/j.jaci.2006.06.011
- 10.1093/jnci/djt265 · DOI
- Berry D, 2016, N Engl J Med, 375, 1592
Cited by
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Primary brain tumours in adults
Lapointe, S., Perry, A., & Butowski, N. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30990-5 · Cited by 1,366
The next generation of evidence-based medicine
Subbiah, V. (2023) · Nature Medicine · doi:10.1038/s41591-022-02160-z · Cited by 544
Past, present and future perspectives in nonalcoholic fatty liver disease
Sanyal, A. J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0144-8 · Cited by 522
Comprehensive analysis of the clinical immuno-oncology landscape
Tang, J., Shalabi, A., & Hubbard-Lucey, V. M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx755 · Cited by 508
Metadata
- Authors
- Woodcock, J., & LaVange, L. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-06
- Volume
- 377
- Issue
- 1
- Pages
- 62-70
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2726405642
- Cited by
- 1,020
- References
- 25
- FWCI
- 58.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.